KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.

Rachael F Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John D Grainger, Jessica Zhang, Linda Smallwood, Emily de León, Brian D Jamieson, AVA-PED-301 Study Group

Lancet Haematol 12(7) e494-e504

PMID40418942
PMCID-
DOI10.1016/S2352-3026(25)00107-3
发表日期2025-05-26
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), taken with food without any specific restrictions, approved for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The aim of this study was to assess the efficacy, safety, tolerability, and pharmacokinetic and pharmacodynamic profile of avatrombopag for children and adolescents with persistent and chronic primary ITP. METHODS: AVA-PED-301 is a global, multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 3b study. Children and adolescents aged ≥1 to <18 years with a confirmed diagnosis of primary ITP for at least 6 months and an insufficient response to a previous treatment were randomly assigned (3:1) to avatrombopag (aged ≥6 years: 20 mg oral tablet once daily; aged ≥1 to <6 years: 10 mg oral suspension once daily) or matching placebo. Doses were titrated to maintain a platelet count of 50-150 × 109 cells per L. The core-phase (12-week double-blind treatment period) full analysis set included all randomly assigned patients; efficacy analysis was performed based on randomised study drug. The safety analysis set included all patients who received at least one dose of study drug in each study phase. The primary endpoint was durable platelet response (proportion of patients with at least six out of eight weekly platelet counts ≥50 × 109 cells per L during the last 8 weeks of the 12-week treatment period in the absence of rescue therapy); the alternative primary endpoint was platelet response (proportion of patients with at least two consecutive platelet assessments ≥50 × 109 cells per L over the 12-week treatment period in the absence of rescue therapy). The trial core phase is complete and was registered with ClinicalTrials.gov (NCT04516967). FINDINGS: Between March 2, 2021, and Aug 2, 2023, 83 children were screened, with 75 randomly assigned to avatrombopag (n=54; 24 [44%] female; 48 [89%] White) or placebo (n=21; 12 [57%] female; 15 [71%] White). 15 (28%) patients in the avatrombopag group met the primary endpoint of durable platelet response versus no (0%) patients in the placebo group (difference in response rate 28% [95% CI 16-40]; p=0·0077); 44 (81%) patients in the avatrombopag group met the alternative primary endpoint of platelet response versus no (0%) patients in the placebo group (difference in response rate 81% [71-92]; p<0·0001). The most common adverse events across treatment groups were petechiae (n=20), epistaxis (n=16), and headache (n=14). Serious adverse events were reported in five (9%) patients in the avatrombopag group and one (5%) patient in the placebo group. No deaths, thromboembolic events, or grade 3 or higher bleeding events were reported. INTERPRETATION: Avatrombopag is an effective oral treatment for children and adolescents with ITP for at least 6 months and has a reassuring safety profile in the paediatric population. Avatrombopag could provide an important treatment option for paediatric ITP. FUNDING: Sobi.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。